Affimed (NASDAQ:AFMD) – Stock analysts at Truist Securiti increased their FY2021 earnings estimates for Affimed in a research note issued to investors on Monday, November 22nd. Truist Securiti analyst S. Devarakonda now anticipates that the biopharmaceutical company will post earnings of ($0.53) per share for the year, up from their prior estimate of ($0.54). Truist Securiti also issued estimates for Affimed’s FY2022 earnings at ($0.90) EPS, FY2023 earnings at ($1.11) EPS and FY2024 earnings at ($0.81) EPS.
AFMD has been the topic of several other research reports. SVB Leerink reaffirmed a “buy” rating and set a $12.00 target price on shares of Affimed in a research report on Sunday, November 14th. Zacks Investment Research upgraded Affimed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 14th. Berenberg Bank started coverage on Affimed in a report on Wednesday, November 17th. They issued a “buy” rating for the company. Stifel Nicolaus initiated coverage on Affimed in a research report on Wednesday, September 29th. They set a “buy” rating and a $12.00 price target for the company. Finally, Truist Securities assumed coverage on Affimed in a research report on Thursday, October 21st. They issued a “buy” rating and a $10.00 target price for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $12.13.
Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Wednesday, November 10th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Affimed had a negative net margin of 132.18% and a negative return on equity of 40.23%. During the same period last year, the business earned ($0.08) earnings per share.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Altium Capital Management LP purchased a new stake in Affimed during the 3rd quarter valued at $4,110,000. BNP Paribas Arbitrage SA boosted its stake in Affimed by 483.3% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 24,940 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 20,664 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Affimed by 126.4% during the 3rd quarter. Janus Henderson Group PLC now owns 1,192,364 shares of the biopharmaceutical company’s stock valued at $7,375,000 after purchasing an additional 665,656 shares during the last quarter. Intellectus Partners LLC boosted its stake in Affimed by 20.7% during the 3rd quarter. Intellectus Partners LLC now owns 188,400 shares of the biopharmaceutical company’s stock valued at $1,164,000 after purchasing an additional 32,300 shares during the last quarter. Finally, Telemetry Investments L.L.C. boosted its stake in Affimed by 47.0% during the 3rd quarter. Telemetry Investments L.L.C. now owns 131,018 shares of the biopharmaceutical company’s stock valued at $810,000 after purchasing an additional 41,910 shares during the last quarter. Institutional investors and hedge funds own 73.02% of the company’s stock.
Affimed Company Profile
Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.
Further Reading: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.